Regulatory consultancy Woodley BioReg is proud to announce a successful collaboration with global healthcare leader Umesh Modi Group.
The company has facilitated the licence application and approval of Wholesale Distribution Authorisation (WDA) for two of the Group’s newly established international businesses.
The approvals enable Universal Trading (UK) Pvt Ltd and Pharma Global (UK) Pvt Ltd to distribute pharmaceuticals outside of India in line with the UK MHRA’s exacting GDP standards.
This represents a major step forward for Umesh Modi Group’s global expansion strategy.
As part of the project, Woodley BioReg also delivered tailored Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) training, helping to embed regulatory best practice into the companies’ operational frameworks from the outset.
Ash Ramzan, founder and Principal Consultant of Woodley BioReg, commented: “We are delighted to have supported the Umesh Modi Group and helped them to achieve GDP authorisation for two of their new international ventures."
"This not only reflects their strategic ambition but also their commitment to regulatory excellence and patient safety. It has been a pleasure to work with such a well-established and forward-looking organisation.”
Mr Umesh Modi, CEO, President and Chair of Umesh Modi Group, added: “Achieving this authorisation is a key milestone for our international growth."
"Woodley BioReg’s expertise in regulatory compliance, licensing and GMP/GDP has been instrumental in helping us meet all required standards efficiently and effectively.”
This success reinforces Woodley BioReg’s position as a trusted regulatory partner for global pharmaceutical and life science companies, offering deep regulatory insight and hands-on support across licensing, compliance and training.